Esperion Therapeutics – (NASDAQ:ESPR)

Finance December 15, 2015

Analysts at RBC Capital Markets Maintain their Past ‘”Outperform”’ rating on Shares Esperion Therapeutics (NASDAQ:ESPR), Set a $40.00 TP

Esperion Therapeutics (NASDAQ:ESPR) Rating Reaffirmed New York: In a note disseminated on Tuesday, 15 December, RBC Capital Markets kept steady their “Outperform” rating on Esperion…

Finance December 15, 2015

68.99% to Target, RBC Capital Mkts Reconfirms ‘”Outperform”’ Rating on Esperion Therapeutics (NASDAQ:ESPR) Shares Today

Esperion Therapeutics (NASDAQ:ESPR) Rating Reaffirmed Recently, In an analyst research report issued to clients on Tuesday morning, Esperion Therapeutics (NASDAQ:ESPR) shares have had their “Outperform”…

Finance December 15, 2015

New York: Esperion Therapeutics (NASDAQ:ESPR) Stock Has Just Had Its “Outperform” Rating Reiterated by RBC Capital Mkts. Shares now Have a $40 Target

Esperion Therapeutics (NASDAQ:ESPR) Rating Reaffirmed In a note shared with investors and clients this morning, RBC Capital Mkts reaffirmed their “Outperform” rating on Esperion Therapeutics…